HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Exogenous gonadotropin therapy in combined anovulatory and male factor infertility.

Abstract
This retrospective study evaluated conception rates in 18 women with refractory anovulatory infertility undergoing hMG ovulation induction in the presence of persistent mild to moderate semen abnormalities. Logistic regression analysis showed no relationship between conception (9.6% cycle) and the age of either partner, primary versus secondary infertility, or lowest sperm count, motility or morphology. In summary, this study demonstrates that a coexisting mild to moderate male factor does not preclude pregnancy during hMG therapy for anovulation. While semen abnormalities should not be ignored, aggressive treatment of concomitant ovulatory disorders and the resulting timed ovulation of several oocytes may minimize the effects of semen abnormalities.
AuthorsM R Fluker, B G Fleige-Zahradka, B H Yuen
JournalActa Europaea fertilitatis (Acta Eur Fertil) 1993 Jan-Feb Vol. 24 Issue 1 Pg. 23-5 ISSN: 0587-2421 [Print] Italy
PMID8303970 (Publication Type: Journal Article)
Chemical References
  • Menotropins
Topics
  • Adult
  • Anovulation (complications, drug therapy)
  • Female
  • Fertilization
  • Humans
  • Infertility, Male (complications)
  • Male
  • Menotropins (therapeutic use)
  • Oligospermia (complications)
  • Ovulation Induction (methods)
  • Pregnancy
  • Pregnancy Outcome
  • Retrospective Studies
  • Sperm Motility
  • Spermatozoa (abnormalities)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: